Ligand Q1 Royalties Surge 56% YoY, Guidance Reaffirmed; Concentration Risk Persists

What happened

Ligand reported Q1 2026 results with royalty revenue up 56% YoY, driven by continued strength in FILSPARI and Ohtuvayre, and reaffirmed full-year guidance including the pending XOMA royalty acquisition. While the strong start supports the base case of FY26 royalty revenue of $200M–$225M, it does not eliminate the concentration risk highlighted in the master report, as the stock at ~$198 already prices in this trajectory. The pending XOMA deal adds future potential but is not yet closed, leaving near-term performance reliant on a few key products. The market's optimism is reflected in the high P/E and EV/EBITDA multiples, which offer limited margin of safety if FILSPARI momentum wanes. Investors should demand further proof of sustained demand before committing new capital.

Implication

The strong Q1 validates royalty growth, but valuation leaves limited upside. A pullback to ~$175 or sustained FILSPARI proof improves risk/reward. XOMA deal adds optionality but is not closed.

Thesis delta

The robust Q1 royalty growth supports the 2026 guidance and base case, but does not alter the thesis that the stock is fully priced. The concentration on FILSPARI and Ohtuvayre remains the key risk. No material change to the WAIT rating; attractive entry at lower levels.